Novartis' Votubia gains CHMP approval; How Exelixis survived losing a partner;

@FierceBiotech: BMS, AZ diabetes drug will face scrutiny. Item | Follow @FierceBiotech

@JohnCFierce: At a Rothschild conference in Cap Ferrat. Remark by Claus Baestrap (former Lundbeck CEO): In-licensed programs do better than in-house. Follow @JohnCFierce

> Novartis' Votubia has been approved by the CHMP for treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex in the EU. The drug is also marketed as Afinitor in the U.S. for neuroendocrine tumor treatment. Story

> Despite more drug approvals and research in the pain arena, many chronic pain sufferers aren't receiving adequate treatment. Item

> When Michael Morrissey took over as head of Exelixis from George Scangos, it came on the heels of Bristol-Myers Squibb dropping the company's partnership on the cancer drug XL184. A year later, Exelixis has more positive results for the drug, but is still fighting Big Pharma's new priorities. Report

> Amsterdam Molecular Therapeutics's Glybera, a lipoprotein lipase deficiency treatment, has been considered not approvable by the European Medicines Agency's Committee for Medicinal Products for Human Use. News

> Brazil Pharma has raised 414 Brazilian reais ($260.3 million) through a 24 million share IPO on the Brazilian Stock Exchange. Item

Pharma News

@FiercePharma: Abbott pushes back closure date on Canadian plant. News | Follow @FiercePharma

> EMA puts off Actos ruling until July. Story

> Novartis drug gets CHMP nod for new use. Article

> Novo plots $191M expansion at Danish plant. Item

And Finally... Josh Bloom, a former Wyeth employee, highlights the growing gap between the number of qualified scientists and potential jobs in the field in a New York Post op-ed. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.